Successful private placement of new Biocartis shares for 33 million EUR
November 17, 2016
On 17 November 2016, Biocartis, an innovative molecular diagnostics company, announced its intention to raise ca. € 25 million in a private placement through an accelerated book building, with the possibility to increase the size of the placement. The offering closed by noon on the same day.
Following strong demand and a significant oversubscription, it was decided to upsize the placement to € 33 million, and to price it at € 8.05 per share, implying a mere 2,4% discount versus the prior day closing price.
The new shares were mostly placed with Belgian and international institutional investors. In April 2015, Degroof Petercam already contributed to the successful IPO of Biocartis.
Degroof Petercam is once more very pleased with the success of this transaction, which demonstrates once again the commitment of Degroof Petercam towards life sciences companies and follows the other successful placement of MDxHealth in recent weeks.